ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

被引：5
|
作者：
Poei, Darin [1 ]
Ali, Sana [2 ]
Ye, Shirley [1 ]
Hsu, Robert [2 ,3 ]
机构：
[1] Univ Southern Calif, Dept Internal Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA
[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Div Med Oncol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA
来源：
CANCER DRUG RESISTANCE | 2024年 / 7卷
关键词：
NSCLC; ALK TKI; acquired resistance; alectinib; crizotinib; lorlatinib; ceritinib; brigatinib; CELL LUNG-CANCER; LYMPHOMA KINASE ALK; GENERATION SEQUENCING REVEALS; PREFERRED 1ST-LINE OPTION; FACTOR RECEPTOR EGFR; OPEN-LABEL; TYROSINE KINASE; PHASE-II; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE;
D O I：
10.20517/cdr.2024.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
引用
收藏
页数：22
相关论文
共 50 条
  • [21] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
    Doebele, Robert Charles
    Aisner, Dara L.
    Le, Anh T.
    Berge, Eamon M.
    Pilling, Amanda B.
    Kutateladze, Tatiana G.
    Weickhardt, Andrew James
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Mechanisms and strategies to overcome resistance to tyrosine kinase inhibitors in lung cancer
    Kobayashi, Susumu
    CANCER SCIENCE, 2018, 109 : 1224 - 1224
  • [23] Mechanisms of acquired resistance to ALK/ROS1 inhibitors
    Shaw, Alice T.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [24] Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies
    Jia, Wenhui
    Huang, Zhao
    Zhou, Li
    Liou, Yih-Cherng
    Di Virgilio, Francesco
    Ulrich, Henning
    Illes, Peter
    Zhang, Wei
    Huang, Canhua
    Tang, Yong
    DRUG RESISTANCE UPDATES, 2023, 70
  • [25] Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
    Saatci, Ozge
    Huynh-Dam, Kim-Tuyen
    Sahin, Ozgur
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2021, 99 (12): : 1691 - 1710
  • [26] Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
    Ozge Saatci
    Kim-Tuyen Huynh-Dam
    Ozgur Sahin
    Journal of Molecular Medicine, 2021, 99 : 1691 - 1710
  • [27] Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance
    Shafi, Sadat
    Khan, Sana
    Hoda, Farazul
    Fayaz, Faizana
    Singh, Archu
    Khan, Mohammad Ahmed
    Ali, Ruhi
    Pottoo, Faheem Hyder
    Tariq, Sana
    Najmi, Abul Kalam
    CURRENT DRUG METABOLISM, 2020, 21 (03) : 199 - 210
  • [28] Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies
    Schiff, Rachel
    Veeraraghavan, Jamunarani
    Fu, Xiaoyong
    CANCER RESEARCH, 2018, 78 (13)
  • [29] ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance
    Pilling, Amanda B.
    Le, Anh T.
    Tan, Aik-Choon
    Kim, Jihye
    Singleton, Katherine R.
    Heasley, Lynn E.
    Helfrich, Barbara
    DeGregori, James
    Doebele, Robert C.
    CANCER RESEARCH, 2012, 72
  • [30] Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
    Qian Fang-Fei
    Han Bao-Hui
    中华医学杂志英文版, 2020, 133 (20) : 2444 - 2455
12345